Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open Label Multi-Center Extension Study to Evaluate the Long-term Safety of Zorblisa™ (SD-101-6.0) in Patients With Epidermolysis Bullosa

NCT02670330 is registered in ClinicalTrials.gov with Scioderm, Inc. as lead sponsor.

NCT NCT02670330
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02670330 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open Label Multi-Center Extension Study to Evaluate the Long-term Safety of Zorblisa™ (SD-101-6.0) in Patients With Epidermolysis Bullosa
Lead sponsor
Scioderm, Inc.
Phase
Phase 3
Overall status
Terminated
Start date
June 9, 2015
Completion date
September 3, 2018
Enrollment
152 (actual)
Sites
30

Conditions

As the registry lists them; a condition with its own page is linked.

epidermolysis bullosa